Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2023 | ECLS-Shock

Cardiogenic shock (CS) represents the main cause of death in patients hospitalized for acute myocardial infarction (AMI). Despite advances in its management, mortality continues to be high, between 40-50% within the first 30 days. In an attempt to improve survival, early extracorporeal life support (ECLS) is being increasingly used to stabilized hemodynamics in cases of serious shock, especially the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO), also called ECLS. 

ESC 2023

Evidence on the efficacy of VA-ECMO in the context of AMI and CS is based mainly on observational studies or small randomized trials. The ECLS-SHOCK is the first randomized clinical trial on VA-ECMO to look into mortality in patients with CS undergoing early revascularization. The study included patients from centers in Germany and Slovenia, mean age 63, and 19% were women.

Primary end point was all-cause mortality at 30 days. Secondary end points included length of mechanical ventilation, time to hemodynamic stabilization and need for renal replacement therapy. As regards safety, researchers looked into bleeding events (from moderate to severe) and peripheral vascular complications requiring intervention. 

Read also: ESC 2023 | STOPDAPT-3.

The final analysis considered a total of 417 patients. Primary end point occurred in 47.8% patients in the VA-ECMO group and 49% in the control group ([RR] 0.98, CI 95%, 0.80-1.19; p=0.81). Length of mechanical ventilation was higher in the VA-ECMO group (7 vs 5 days). Also, time to hemodynamic stabilization and need for renal replacement therapy rate were similar.  

As regards safety end points, there were more bleeding events in the VA-ECMO group (RR 2.44, CI 95% 1.50-3.95) and more interventions for peripheral vascular complications (RR 2.86, CI 95% 1.31-6.25).

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented at the Hot Line Sessions, Agosto 26, ESC Congreess 2023, Amsterdam.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...